HDAC9 and atherosclerosis: While the role of MPO in atherosclerosis, particularly in its interactions with LDL and HDL, has been extensively addressed in several recent reviews [60–65], and the progress in therapeutic applications of Histone Deacetylases (HDAC) inhibitors (both selective and pan-HDAC inhibitors) in atherosclerosis has been thoroughly explored [66–71], this manuscript aims to bring new insights by integrating the latest findings in the field.